Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To ...

Retrieved on: 2025-01-23 16:51:49

Tags for this article:

Click the tags to see associated articles and topics

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To .... View article details on hiswai:

Excerpt

Vigil Neuroscience's VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 reduction, and potential Alzheimer's treatment; Phase 2 begins Q3 2025.

Article found on: www.benzinga.com